IGHE and allergic disease: Overall, the strong involvement of IL-1β in allergic diseases (Figure 3) means that treatments aimed at down-regulating this cytokine and its signaling pathways are attractive therapeutic options during acute and chronic manifestations to reduce the symptoms of IgE-mediated inflammation.